Burkina Faso vs Central African Republic: Antiretroviral therapy coverage for PMTCT
Burkina Faso
69.0%
in 2024
Central African Republic
69.0%
in 2024
Burkina Faso rank
52nd
Central African Republic rank
52nd
Antiretroviral therapy coverage for PMTCT over time
- Burkina Faso
- Central African Republic
How they compare
Burkina Faso currently reports 69.0% against 69.0% in Central African Republic, a difference of 0.0%.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Central African Republic ahead.
Burkina Faso ranks 52nd and Central African Republic ranks 52nd of 84 countries.
Burkina Faso has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Burkina Faso | Central African Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 10.0% | 9.0% | 1.0% | Burkina Faso |
| 2010s | 51.5% | 40.7% | 10.8% | Burkina Faso |
| 2020s | 79.8% | 59.2% | 20.6% | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Burkina Faso or Central African Republic?
- Burkina Faso, at 69.0% against 69.0% in Central African Republic as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Burkina Faso and Central African Republic?
- 0.0%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Central African Republic?
- 25 years are reported by both, from 2000 to 2024.
- How do Burkina Faso and Central African Republic rank globally for antiretroviral therapy coverage for pmtct?
- Burkina Faso ranks 52nd and Central African Republic ranks 52nd of 84 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).